QAX576 placebo

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

AsthmaEosinophilic EsophagitisKeloids

Phase 1

To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma

CompletedNCT01568762

Novartis PharmaceuticalsAsthma

Start: 2010-10-31Updated: 2020-12-21

Phase 2

Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence

TerminatedNCT00987545

Novartis PharmaceuticalsKeloids

Start: 2009-06-30End: 2010-11-30Updated: 2020-12-19

Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis

CompletedNCT01022970

Novartis PharmaceuticalsEosinophilic Esophagitis

Start: 2009-11-30Updated: 2021-03-11